Figure 2From: An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab Immunofluorescence assay in HEK cells. Co-localization of fluorescent labeling was detected in cells expressing AQP4-EGFP when a direct fluorescence signal was observed (A) or when serum from an NMO patient was used as the primary antibody (NMO-IgG) in an immunoassay (B).Back to article page